Leukemia, Myeloid, Acute: all 3,035 studies

Page 21 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.

• Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantActive, not recruitingNCT03622788Phase 1/2
• Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITDCompletedNCT03622541Phase 2
• Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03616470Phase 3
• Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPNActive, not recruitingNCT03613532Phase 1
• Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)Active, not recruitingNCT03609060Phase 2
• Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction ChemotherapyActive, not recruitingNCT03603795Phase 2
• Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationWithdrawnNCT03602898Phase 2
• Efficacy of FLAG Regimen for the Treatment of Patients With AMLStatus unknownNCT03600558
• Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT03600155Phase 1
• Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AMLActive, not recruitingNCT03597321Phase 2
• COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeActive, not recruitingNCT03595787Not applicable
• Efficiency of Antibacterial Prophylaxis in Azacitidine Treated PatientsCompletedNCT03594149Phase 3
• A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AMLActive, not recruitingNCT03591510Phase 2
• NGS in AML RelapseStatus unknownNCT03582241
• Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)CompletedNCT03568994Early Phase 1
• Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)CompletedNCT03564288Phase 1
• A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid LeukemiaCompletedNCT03563560Phase 1
• Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 MutationWithdrawnNCT03560908Phase 1
• A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type MalignanciesActive, not recruitingNCT03560882Phase 1
• The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative NeoplasmStatus unknownNCT03558607Phase 1/2
• CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）Status unknownNCT03556982Phase 1/2
• Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for SurvivalTerminatedNCT03549351
• A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AMLTerminatedNCT03547115Phase 1
• Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AMLCompletedNCT03537560
• A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaTerminatedNCT03530683Phase 1
• Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCTStatus unknownNCT03530085Phase 2/3
• A Post-Marketing Observational Study of VYXEOS™CompletedNCT03526926
• Ascorbic Acid Levels in MDS, AML, and CMML PatientsCompletedNCT03526666
• EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute LeukemiaTerminatedNCT03519984Phase 1
• Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid LeukemiaTerminatedNCT03516760Phase 1
• Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid LeukemiaWithdrawnNCT03515707Phase 2
• IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell TransplantationCompletedNCT03515512Phase 1
• Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT03513484Phase 1
• IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic SyndromeActive, not recruitingNCT03503409Phase 2
• Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted TherapyStatus unknownNCT03499912
• Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic SyndromeSuspendedNCT03494569Phase 1
• Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486CompletedNCT03493646Phase 2
• Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML PatientsCompletedNCT03488862
• A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03484520Phase 1
• Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid LeukemiaTerminatedNCT03483948Phase 1
• CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03473457Not applicable
• Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT03467386Phase 1
• Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDSCompletedNCT03459859Phase 1
• Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid LeukemiaCompletedNCT03455504Phase 2
• Immune Checkpoint Receptors in AML-Leukemic Initiating CellsCompletedNCT03449745
• AML Electronic Decision AidCompletedNCT03442452Not applicable
• A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03441555Phase 1
• Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03441048Phase 1
• Micro-transplantation in Elderly Patients With Acute Myeloid LeukemiaTerminatedNCT03439371Not applicable
• Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction TherapyCompletedNCT03435848Phase 2
• Survival in Patients Older Than 60 Years With Newly Diagnosed AML in SpainCompletedNCT03435341
• Observational Study of Spatio-Temporal Patterns of New Cases of Acute Myeloid LeukemiaCompletedNCT03433521
• Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and ChemotherapyActive, not recruitingNCT03422731Early Phase 1
• MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)Status unknownNCT03412292Phase 1
• Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)TerminatedNCT03410407
• Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)No longer availableNCT03409081
• Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic SyndromeTerminatedNCT03404193Phase 2
• TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic AcidCompletedNCT03397173Phase 2
• CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic SyndromeCompletedNCT03393611Phase 1
• Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid LeukemiaCompletedNCT03389724Phase 3
• Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)CompletedNCT03388749Phase 1/2
• Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 MutationsStatus unknownNCT03381781Phase 2
• Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML PatientsTerminatedNCT03381118Phase 2
• Psychological Intervention Mobile App for Patients With AMLCompletedNCT03372291Not applicable
• QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AMLWithdrawnNCT03365661Phase 2
• A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) CancerTerminatedNCT03360006Phase 1
• DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast ExcessStatus unknownNCT03356080Phase 2
• Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.CompletedNCT03350152
• Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT03347994Phase 1
• Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2CompletedNCT03338348Phase 2
• Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional BiomarkersStatus unknownNCT03337516Not applicable
• Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and NeutropeniaCompletedNCT03333005Phase 1
• A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid LeukemiaWithdrawnNCT03324243Phase 2
• Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.CompletedNCT03311815
• A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive TherapyActive, not recruitingNCT03310918Not applicable
• NLA101 in Adults Receiving High Dose Chemotherapy for AMLTerminatedNCT03301597Phase 2
• Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantActive, not recruitingNCT03301168Phase 1/2
• A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction ChemotherapyCompletedNCT03298516Phase 1
• Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid LeukemiaWithdrawnNCT03291353Early Phase 1
• Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®Status unknownNCT03287128
• Ruxolitinib + Allogeneic Stem Cell Transplantation in AMLActive, not recruitingNCT03286530Phase 2
• Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life ConditionActive, not recruitingNCT03284593
• Cd11b and Cd56 as Prognostic Markers in Acute Myeloid LeukemiaStatus unknownNCT03283228
• Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells AllograftCompletedNCT03280290Not applicable
• Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
• Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 StudyStatus unknownNCT03260101
• A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years OldStatus unknownNCT03257241Phase 3
• Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCTStatus unknownNCT03256071Phase 2/3
• Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03247088Phase 1/2
• Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 MutationApproved for marketingNCT03245424
• A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory MalignanciesCompletedNCT03236857Phase 1
• Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic SyndromesStatus unknownNCT03235973Phase 1
• Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid LeukemiaCompletedNCT03234985
• Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy DonorsTerminatedNCT03233074
• HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid HemopathiesCompletedNCT03232268Phase 1
• Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.TerminatedNCT03218683Phase 1
• Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.TerminatedNCT03217838Phase 1
• iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)WithdrawnNCT03207334Phase 2
• Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT03207191Phase 1
• IDH1/IDH2 Mutation Frequency in Acute Myeloblastic PatientsStatus unknownNCT03204838

← Leukemia, Myeloid, Acute overview